Clinical Trial Update: Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide [Phase 2, Phase 3]

View source ↗

Summary

Phase 2b/3 trial update evaluating switching to Brelovitug for chronic hepatitis D in participants receiving Bulevirtide; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis D

Drugs mentioned

• Brelovitug (BJT-778)
• Bulevirtide (bulevirtide)

Snippet

Sponsor: Mirum Pharmaceuticals, Inc. | Conditions: Chronic Hepatitis D | Phase 2, Phase 3 | Status: RECRUITING